FDA Draft Guidance on Duchenne: Telebriefing

On June 25, 2014, we shared the first-ever rare disease patient-initiated guidance with FDA to help accelerate treatments for Duchenne. This new guidance focuses on overcoming challenges in clinical trial design across six key areas. It is our profound hope that this effort will lead to the approval of much needed treatments for all people living with Duchenne.

Download the recording of our telebriefing to learn more about the guidance, the 80+ expert stakeholders who contributed, and our next steps.

Views: 331


You need to be a member of PPMD Community to add comments!

Join PPMD Community

Need help using this community site? Visit Ning's Help Page.



© 2021   Created by PPMD.   Powered by

Badges  |  Report an Issue  |  Privacy Policy  |  Terms of Service